New Data & amp; Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)
Dr. Daniel Goldstein considers new data by Clarke & colleagues on a combination of the PARP inhibitor olaparib with abiraterone for molecularly unselected metastatic prostate cancer, along with pr...
Author: BeaconMedIC
Added: 08/28/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts